Ozagrel (hydrochloride)

Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2) . Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases[1][2][3][4][5].

Product Specifications

CAS Number

[78712-43-3]

Product Name Alternative

OKY-046 (hydrochloride)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ozagrel-hydrochloride.html

Purity

99.86

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

Smiles

[H]Cl.O=C(O)/C=C/C1=CC=C(CN2C=CN=C2)C=C1

Molecular Formula

C13H13ClN2O2

Molecular Weight

264.71

Precautions

H302, H315, H319, H335

References & Citations

[1]Ishitsuka Y, et al. A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009 Oct;111 (2) :211-5.|[2]Saito MS, et al. Antiplatelet pyrazolopyridines derivatives: pharmacological, biochemical and toxicological characterization. J Enzyme Inhib Med Chem. 2016 Dec;31 (6) :1591-601.|[3]Bhatia P, Singh N. Ameliorative effect of ozagrel, a thromboxane A2 synthase inhibitor, in hyperhomocysteinemia-induced experimental vascular cognitive impairment and dementia. Fundam Clin Pharmacol. 2021 Aug;35 (4) :650-666.|[4]Bhatia P, Kaur G, Singh N. Ozagrel a thromboxane A2 synthase inhibitor extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced vascular dementia. Vascul Pharmacol. 2021 Apr;137:106827.|[5]Nakazawa M, et al. [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi. 1994;114 (12) :911-33.